This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions
Examples
ActivityDefinition
ArtifactAssessment
Citation
- 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
- 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
- 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
- 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
- 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
- 19967827 Wonder woman was Argentine and her real name was Evita.
- 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
- 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
- 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
- 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
- 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
- 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
- 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
- 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
- 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
- 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
- 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
- 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
- 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
- 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
- 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
- 29202628 “I Kinda Feel Like Wonder Woman”: An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
- 29357271 Using Hawkeye from the Avengers to communicate on the eye.
- 29694275 A regressive formula of perversity: Wertham and the women of comics.
- 29694302 Introduction: “Suffering Sappho!”: Lesbian content and queer female characters in comics.
- 30467172 Finding my inner Wonder Woman.
- 34871555 What Can Wonder Woman Teach Radiologists?
- 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
- 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
- 6907780 Career guide: to change what needs changing…doesn’t take Wonder Woman.
- Anticoagulation for COVID-19 Combined RCTs in NEJM
- BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
- BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
- BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
- Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
- Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
- DatabaseCitation: Citation for FEvIR Platform
- DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
- DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
- Delany-Moretlwe 2022 clinical trial
- JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
- JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
- PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
- SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
- StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
- WebPageCitation: A HEvKA Update Summary
Composition
DeviceDefinition
Evidence
EvidenceVariable
Group
Library
List
Organization
PlanDefinition
|
Propose a change